Business Context and Reporting Period
This Form 8-K was filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc.) on July 14, 2023. The report details the entry into a material definitive agreement to facilitate the sale of common stock.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the authorization of a potential equity offering:
- Maximum Offering Size: Up to $6.7 million in aggregate offering price.
- Commission Fee: 3.0% of the gross sales price paid to the agent.
- Trading Symbol: VIRI (Nasdaq Capital Market).
Material Changes
On July 14, 2023, the Company entered into a Capital On Demand Sales Agreement with JonesTrading Institutional Services LLC. This agreement allows the Company to sell shares of its common stock through an "at the market" offering. The Company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Risks
Management Commentary: The Company may sell shares from time to time based on its instructions, including price, time, or size limits. The agreement may be terminated by either party at any time upon notice.
Risks and Contingencies: The filing notes that the sale of shares is subject to market conditions and the Company's discretion. No specific financial guidance or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the correct registrant name is Virios Therapeutics, Inc., not Dogwood Therapeutics, Inc.
- Confirm the total amount of shares sold under this agreement in subsequent filings.
- Review the Company's effective Form S-3 Registration Statement (No. 333-263700) for full terms.
- Monitor the Company's cash position to determine if the $6.7 million cap will be utilized.